Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery

2020 ◽  
Author(s):  
M. Stenman ◽  
H. Benmakhlouf ◽  
P. Wersäll ◽  
P. Johnstone ◽  
M. A. Hatiboglu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gamma Knife ◽  
Metastatic Renal Cell Carcinoma ◽  
Patient Selection ◽  
Renal Cell ◽  
Gamma Knife Radiosurgery ◽  
Selection For ◽  
The Brain

Gamma knife radiosurgery for renal cell carcinoma brain metastases

2002 ◽  
Vol 97 ◽  
pp. 489-493 ◽  
Author(s):  
Laura Hernandez ◽  
Lucia Zamorano ◽  
Andrew Sloan ◽  
James Fontanesi ◽  
Simon Lo ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Gamma Knife ◽  
Median Survival ◽  
Renal Cell ◽  
Univariate Analysis ◽  
Gamma Knife Radiosurgery ◽  
Content Type ◽  
Fine Print

Object. The purpose of this study was to clarify the effectiveness of gamma knife radiosurgery (GKS) in achieving a partial or complete remission of so-called radioresistant metastases from renal cell carcinoma (RCC) and to propose guidelines for optimal treatment Methods. During a 5-year period, 29 patients (19 male and 10 female) with 92 brain metastases from RCC underwent GKS. The median tumor volume was 4.7 cm3 (range 0.5–14.5 cm3). Fourteen patients (48%) also underwent whole-brain radiotherapy (WBRT) before GKS, and two patients (6.8%) after GKS. The mean GKS dose delivered to the 50% isodose at the tumor margin was 16.8 Gy (range 13–30 Gy). All cases were categorized according to the Recursive Partitioning Analysis (RPA) classification for brain metastases. Univariate analysis was performed to determine significant prognostic factors and survival. The overall median survival was 7 months after GKS treatment. Age, sex, Karnofsky Performance Scale score, and controlled primary disease were not predictors of survival. Combined WBRT/GKS resulted in median survival of 18, 8.5, and 5.3 months for RPA Classes I, II, and III, respectively, compared with the median survival 7.1, 4.2, and 2.3 months for patients treated with WBRT alone. Conclusions. These results suggest that WBRT combined with GKS may improve survival in patients with brain metastases from RCC. Furthermore, this improvement in survival was seen in all RPA classes.

scholarly journals Treatment selection for first‐line metastatic renal cell carcinoma in Australia: Impact of new therapy options

2019 ◽  
Vol 15 (S10) ◽  
pp. 3-10 ◽  
Author(s):  
Andrew Schmidt ◽  
Arun Azad ◽  
Jeffrey Goh ◽  
Carole Harris ◽  
Anthony M. Joshua ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Treatment Selection ◽  
First Line ◽  
Therapy Options ◽  
New Therapy ◽  
Selection For
Sign in / Sign up

Export Citation Format

Share Document